We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FICO:NYSEFair Isaac Corporation Analysis

Data as of 2026-04-03 - not real-time

$1,089.76

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Fair Isaac Corp (FICO) is trading at $1,089.76, which sits well beneath its 20‑day (≈$1,141), 50‑day (≈$1,301) and 200‑day (≈$1,544) simple moving averages, signaling a bearish price environment. The 14‑day RSI of 40.9 hints at modest oversold pressure, while the MACD histogram is positive (+5.2), suggesting a faint short‑term bullish tilt. Volume is on a decreasing trend and 30‑day volatility is extreme at 73 %, amplifying downside risk. Fundamentally, the company posts robust 16.4 % revenue growth and impressive margins (gross ≈ 83 %, operating ≈ 45 %). However, the current price is more than double the DCF‑derived fair value of $514, delivering an implied upside of ~72 % that appears unrealistic given a forward PE of 20.5 versus an industry average of 33.5. A recent $1.5 billion share‑buyback program and a consensus “buy” rating provide a positive catalyst, but the technical bearishness and high valuation temper enthusiasm.
Given the stark disparity between market price and intrinsic estimates, investors should treat FICO as overvalued in the near term. The company’s high‑margin software franchise and recurring scoring revenues support a longer‑run growth narrative, yet the combination of elevated volatility, bearish momentum, and a hefty price premium suggest caution. A disciplined approach that weighs the upside potential against the technical downside and sector‑specific AI‑related headwinds is advisable.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below all major moving averages
  • Decreasing volume and high short‑term volatility
  • Technical bearish momentum despite minor MACD bounce

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth and high operating margins
  • Forward PE compression to ~20 indicating earnings expansion
  • Announced $1.5 billion share‑buyback program as a catalyst

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Durable, recurring scoring and analytics revenue streams
  • Strategic positioning in AI‑driven decision software
  • Long‑term upside potential relative to DCF fair value

Key Metrics & Analysis

Financial Health

Revenue Growth16.40%
Profit Margin31.89%
P/E Ratio40.4
ROA34.76%
P/B Ratio-14.3
Op. Cash Flow$758.9M
Free Cash Flow$573.2M
Industry P/E33.5

Technical Analysis

TrendBearish
RSI40.9
Support$969.32
Resistance$1,481.46
MA 20$1,140.90
MA 50$1,300.87
MA 200$1,543.70
MACDBullish
VolumeDecreasing
Fear & Greed Index78.8

Valuation

Fair Value$513.70
Target Price$1,872.18
Upside/Downside71.80%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.91
Volatility73.14%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.